Psychiatric News (7/29) reported, “People with schizophrenia who take long-acting injectable antipsychotics (LAIs) have a lower risk of disease relapse, healthcare use, and adverse events such as suicide attempts compared with those who take oral antipsychotics,” researchers concluded after examining “data from the electronic health records of 70,396 adults with schizophrenia who were prescribed at least one LAI and at least one oral antipsychotic between 2004 and 2019,” then comparing “the rates of different health outcomes during periods when patients were taking only LAIs with the periods when patients were taking only oral antipsychotics.” The findings were published online July 28 in JAMA Network Open.
Related Links:
— “Suicide, Relapse Risk Lower When Schizophrenia Patients Take Long-Acting Injectables, Psychiatric News, July 29, 2022